bone marrow biopsy – processing dr epari sridhar associate professor pathology

41
Bone Marrow biopsy – processing Dr Epari Sridhar Associate Professor Pathology

Upload: tabitha-watling

Post on 01-Apr-2015

233 views

Category:

Documents


12 download

TRANSCRIPT

Page 1: Bone Marrow biopsy – processing Dr Epari Sridhar Associate Professor Pathology

Bone Marrow biopsy – processing

Dr Epari Sridhar

Associate Professor

Pathology

Page 2: Bone Marrow biopsy – processing Dr Epari Sridhar Associate Professor Pathology

Introduction• Examination of the bone marrow (BM) aspirate and

trephine biopsy is essential for the diagnosis of BM disorders.

• A comprehensive diagnosis of a BM disorder often requires the integration of various diagnostic approaches:– peripheral blood (PB) counts and smear evaluation, – BM aspirate and imprint smear, BM trephine biopsy – Other investigations such as cytochemistry, immunophenotypic

analysis, cytogenetic and molecular genetic techniques,– Biochemical and microbiological test results, as appropriate.

• The aspirate and trephine biopsy provide complementary and useful information.

• It is recommended that both BM aspirate and biopsy be routinely performed so that respective findings can be correlated.

Page 3: Bone Marrow biopsy – processing Dr Epari Sridhar Associate Professor Pathology

BM - Indications• Unexplained anaemia, abnormal red cell indices, cytopenias or

cytoses• Abnormal peripheral blood smear morphology suggestive of bone

marrow pathology• Diagnosis, staging and follow-up of malignant haematological

disorders (e.g. leukaemias, MDS, Myeloproliferative disorders, lymphomas, myeloma, amyloidosis, mastocytosis)

• Suspected bone marrow metastases• Unexplained focal bony lesions on radiological imaging• Unexplained organomegaly or presence of mass lesions inaccessible

for biopsy• Microbiological culture for investigations of pyrexia of unknown origin

or specific infections, e.g. military tuberculosis, leishmaniasis, malaria• Evaluation of iron stores• Investigation of lipid/glycogen storage disorders• Exclusion of haematological disease in potential allogeneic stem cell

transplant donors

Page 4: Bone Marrow biopsy – processing Dr Epari Sridhar Associate Professor Pathology

BM BX - Prerequisites

•The procedure should be explained in detail to the patient. •History of any allergies should be obtained and co- morbidities documented and any premedications explained.•Informed consent should be obtained from the patient. •A blood count and smear should be obtained if these have not been collected in the previous 2 days.

•Awareness of the indications for the marrow examination and the specimens required to be taken. •Should be done under adequate sedation and analgesia, if required •Safety issues with regard to thrombocytopenia or coagulopathic risks

Page 5: Bone Marrow biopsy – processing Dr Epari Sridhar Associate Professor Pathology

Site for BM aspiration and trephine biopsy

• The preferred site is the posterior iliac crest. – Anterior iliac crest can be used if the patient is immobile.– Medial surface of the tibia can also be used in infants. – Sternal aspirate may be appropriate in certain

circumstances, e.g. immobile pts, prior RT to the pelvis or other sites have yielded a ‘dry tap’ or if a trephine biopsy is not required.

– Sternal aspiration should not be attempted in patients with suspected plasma cell myeloma or other disorders associated with bone resorption.

– If there is a known focal bone lesion (from radiological imaging), diagnostic information may be obtained if a needle aspirate and bone biopsy is also performed at the site.

Page 6: Bone Marrow biopsy – processing Dr Epari Sridhar Associate Professor Pathology

Positioning the Patient

• Posterior iliac crest (PIC) Lateral decubitus position, knees flexed, pillow under head, eyes away

• Anterior iliac crest (AIC) - Supine position, hips and knees flexed, eyes away

• Sternum Supine position, head and eyes away, light towel over face "to keep things sterile" (and cover eyes)

Right posterior iliac crest

Page 7: Bone Marrow biopsy – processing Dr Epari Sridhar Associate Professor Pathology

Site: BMA vs BMBX• Either the aspirate or the trephine biopsy may be

performed first.– Aspirate is usually performed first but, if a very large

aspirate is taken, this may lead to suboptimal trephine biopsy specimen.

– Probability of obtaining an adequate aspirate is less if aspiration is performed after biopsy.

– It is also easier to perform the least painful procedure first.

• But both should preferable be done in the same sitting with sites be appr 0.5-1cms apart.

• It is recommended that the aspirate and trephine biopsy be obtained using the respective needles separately, and not through a trephine needle.

Page 8: Bone Marrow biopsy – processing Dr Epari Sridhar Associate Professor Pathology

Commercial kit – BMBX & BMA

Various needle designs are satisfactory including Jamshidi and Islam needles.

Page 9: Bone Marrow biopsy – processing Dr Epari Sridhar Associate Professor Pathology

BMBX – Specimen collection• The length of the core from an adult should be at least 2 cm.

– A shorter core (e.g. 1 cm) may sometimes contain sufficient diagnostic information.

– Bilateral trephine biopsies may be performed to increase the yield of detecting focal lesions.

• The specimen should be handled gently to avoid crush artefact and distortion. – a blunt stylet should be used to expel the core from the proximal end of

the biopsy needle onto a glass slide. • Touch imprints should be made from the trephine biopsy prior to

placing in fixative.– Imprints are made by gently touching the fresh unfixed core on the

slide, or the slide on the core. • After the imprints have been made, the core specimen should be

placed into a container with appropriate fixative. – The container must be appropriately labeled at the bedside with the

patient surname, first name, unique patient identifier, and – date and time of collection, should be mentioned on the label, so that

the time when the biopsy specimen should be removed from the fixative can be calculated.

Page 10: Bone Marrow biopsy – processing Dr Epari Sridhar Associate Professor Pathology

Adequacy of the biopsy

• Should contain at least five to six intertrabecular spaces and, after processing (at least 2–3 cm in length; 1.5–2 cm is an acceptable length.)– The amount of assessable haemopoietic marrow

included in the biopsy specimen is of more importance than the total length.

– In the case of children, biopsies will necessarily be shorter.

• A higher detection rate with bilateral biopsies has been demonstrated for neuroblastoma, small cell carcinoma of the lung, lymphoma.

Page 11: Bone Marrow biopsy – processing Dr Epari Sridhar Associate Professor Pathology

BM BX - Fixation• Fixation methods can significantly affect morphology,

cytological detail and immunoreactivity. • A standard fixative is neutral buffered formalin for 6 h. • Other fixatives commonly used include

– zinc formaldehyde, – B5 (mercuric chloride, sodium acetate and formalin), – AZF (acetic acid-zinc-formalin), – IBF (isotonic buffered formalin), – Bouin’s fixative (picric acid, acetic acid and formaldehyde),– Formaldehyde and glutaraldehyde.

• Fixation time varies depending on the fixative used, from a minimum of 1 h to maximum of >24 h.

• Neutral buffered formalin with EDTA decalcification gives adequate morphology, preserves antigens for IHC and nucleic acids for molecular studies.

Page 12: Bone Marrow biopsy – processing Dr Epari Sridhar Associate Professor Pathology

BM BX - Decalcification• Commonly used solutions are EDTA, formic acid, acetic• acid, picric acid, nitric acid • Commercial decalcifying agents (e.g. Shandon TBD.1,

Basingstoke, Hampshire, UK; Surgipath Decalcifier II, Richmond,IL, USA).

• Decalcification time varies from 15 min to 72 h, depending both on the type of decalcifying agent as well as on the size of the biopsy specimen.– Decalcification chelates storage iron, affects morphology and

cytological detail, the ability to perform histochemistry and IHC, and to retrieve material suitable for molecular analysis.

– Decalcification with EDTA results in better preservation of nucleic acids, but is slower than with other acid reagents.

Page 13: Bone Marrow biopsy – processing Dr Epari Sridhar Associate Professor Pathology

Processing and Sectioning

• After decalcification, the biopsy specimen is processed in the same manner for other histopathology specimens for paraffin embedding and sections cut on a microtome.

• The recommended thickness of sections is 2-3 microns. – At least six sections should be cut at three

levels: 25%, 50%, and 75% into the cross-sectional diameter of the core.

Page 14: Bone Marrow biopsy – processing Dr Epari Sridhar Associate Professor Pathology

BM BX - Plastic embedding

• Bone marrow core biopsy specimens can also be embedded in plastic resin.

• Gives good cytological detail, does not require decalcification and may be useful for the evaluation of metabolic bone diseases and histochemical reactions.

• But is technically more difficult and limits the range of immunohistochemical studies and probably FISH.

Page 15: Bone Marrow biopsy – processing Dr Epari Sridhar Associate Professor Pathology

J Clin Pathol. 2006 Sep;59(9):903-11.Optimal processing of bone marrow trephine biopsy: the Hammersmith Protocol.Naresh KN, Lampert I, Hasserjian R, Lykidis D, Elderfield K, Horncastle D, Smith N, Murray-Brown W, Stamp GW.SourceDepartment of Histopathology, Hammersmith Hospital, London, UK. [email protected]

AbstractSpecimens of bone marrow trephine biopsy (BMT) are transported and fixed in acetic acid-zinc-formalin fixative, decalcified in 10% formic acid-5% formaldehyde and processed with other specimens to paraffin-wax embedding. Sections, 1-microm-thick, are cut by experienced histotechnologists and used for haematoxylin and eosin, Giemsa, reticulin silver and other histological stains. Further, all immunohistochemical procedures used in the laboratory, including double immunostaining, can be used on these sections with no or minimal modifications. About 10,000 BMT specimens have been analysed using this procedure since 1997 and diseases involving the bone marrow have been classified successfully. More recently, standardised polymerase chain reaction-based analysis and mRNA in situ hybridisation studies have been conducted. Excellent morphology with good antigen, DNA and RNA preservation is offered by the Hammersmith Protocol.

Page 16: Bone Marrow biopsy – processing Dr Epari Sridhar Associate Professor Pathology

BM BX - Staining

• Sections should be stained with haematoxylin and eosin (H&E).– Giemsa staining may be carried out in addition to H&E

stains. – Giemsa stain may be helpful for identifying plasma cells,

mast cells, lymphoid cells, eosinophils, and for distinguishing between myeloblasts and proerythroblasts.

– One section may be stained for reticulin by the silver impregnation method.

– A trichrome stain may be used to identify collagen fibrosis, which is readily recognized in well-stained H&E specimens.

Page 17: Bone Marrow biopsy – processing Dr Epari Sridhar Associate Professor Pathology

Microscopy

• Two to four sections should be reviewed routinely. – In staging, the chances of detecting a focal lesion are

increased if more sections are reviewed.

• Particularly useful for the assessment of overall marrow architecture and cellularity and provide greater sensitivity for the assessment of focal lesions and patchy infiltrates.

Page 18: Bone Marrow biopsy – processing Dr Epari Sridhar Associate Professor Pathology
Page 19: Bone Marrow biopsy – processing Dr Epari Sridhar Associate Professor Pathology

BM BX - cellularity • The percentage cellularity should be obtained by estimating

the proportion of cells occupying the total marrow cavity.

– BM cellularity varies with age and should be assessed with reference to the age of the patient.

– In healthy paediatric samples, cellularity is highest in patients younger than 2 years (approximately 80%), and declines in patients 2 to 4 years old (approximately 70%) and 5 to 9 years old (approximately 60%).

– Generally, iliac crest specimens gradually decrease from 60% cellularity after puberty to 30% by the 8th decade.

– – Intertrabecular spaces adjacent to the cortex are frequently

hypocellular, particularly in the elderly, and should not be included in the assessment of cellularity.

Page 20: Bone Marrow biopsy – processing Dr Epari Sridhar Associate Professor Pathology
Page 21: Bone Marrow biopsy – processing Dr Epari Sridhar Associate Professor Pathology
Page 22: Bone Marrow biopsy – processing Dr Epari Sridhar Associate Professor Pathology
Page 23: Bone Marrow biopsy – processing Dr Epari Sridhar Associate Professor Pathology

Microscopy ..contd.

• Trephine sections should be viewed systematically - initially at low power (4x to 10x) for:– adequacy, pattern, cellularity, presence of focal lesions,

megakaryocyte number, abnormal cell clusters and location

– bone structure (trabecular number and thickness), and osteoclastic and osteoblastic activity.

• The sections are next viewed under higher magnification (20x to 40x) to assess haemopoietic activity (e.g. erythroid, myeloid, megakaryocytic lineages, lymphoid cells, plasma cells and macrophages) and cytological detail.

Page 24: Bone Marrow biopsy – processing Dr Epari Sridhar Associate Professor Pathology

BM BX - Cellular distribution• Granulocytic precursors in the marrow are

anatomically related to paratrabecular and perivascular locations.

• Erythroid precursors occur in islands that appear randomly distributed in the marrow spaces but are generally related to perivascular location

• Megakaryocytes are ususally randomly distributed throughout the bone marrow and usually occur singly

Page 25: Bone Marrow biopsy – processing Dr Epari Sridhar Associate Professor Pathology
Page 26: Bone Marrow biopsy – processing Dr Epari Sridhar Associate Professor Pathology
Page 27: Bone Marrow biopsy – processing Dr Epari Sridhar Associate Professor Pathology
Page 28: Bone Marrow biopsy – processing Dr Epari Sridhar Associate Professor Pathology
Page 29: Bone Marrow biopsy – processing Dr Epari Sridhar Associate Professor Pathology

BM BX – lymphoid cells

• Appr 10% of marrow cells in adults are small lymphocytes.– Diffusely scattered throughout the interstitium– Reactive aggregates amy be seen, especially

in older age (more frequent after 4th decade; F>M).

• Plasma cells are usually <1%– Usually in the perivascular location

Page 30: Bone Marrow biopsy – processing Dr Epari Sridhar Associate Professor Pathology

BM BX - Stromal component

• Comprises of adipose tissue with sinusoids, fibroblasts etc.– Adipose tissue: serous

degeneration/gelatinous tranformation– Stromal fibrosis– Sinusoids:

• Inconspicous under normal circumstances• Dilated: sudden loss of the cellularity or in cases of

the tumour infiltration

Page 31: Bone Marrow biopsy – processing Dr Epari Sridhar Associate Professor Pathology

BM BX - reticulin

• Quantification of reticulin staining - Two grading systems– European consensus scoring system: from 0 to 3 – Bauermeister scoring system: from 0 to 4 . – The scoring system used must be stated.

• May also be graded as normal, slightly increased, moderately increased, markedly increased or absent.

• Focal increase in reticulin (e.g. seen after therapy) should be commented on if necessary for diagnosis.

Page 32: Bone Marrow biopsy – processing Dr Epari Sridhar Associate Professor Pathology

Reticulin grading system

Page 33: Bone Marrow biopsy – processing Dr Epari Sridhar Associate Professor Pathology
Page 34: Bone Marrow biopsy – processing Dr Epari Sridhar Associate Professor Pathology
Page 35: Bone Marrow biopsy – processing Dr Epari Sridhar Associate Professor Pathology
Page 36: Bone Marrow biopsy – processing Dr Epari Sridhar Associate Professor Pathology

Other ancillary investigations• Useful histochemical stains include Congo Red, Ziehl-

Nielsen stain, Gomori’s methenamine silver (GMS) stain, and the periodic acid Schiff (PAS) .– If the aspirate is a dry or aparticulate tap, sections may

be stained with Prussian Blue to assess storage iron, however decalcification removes storage and sideroblast iron.

• Immunohistochemistry: for the determination of the lineage and differentiation stage of normal or abnormal cells or cellular infiltrates, detection of low level or minimal residual disease, disease classification and detecting markers of prognosis.– Some phenotypic markers can be assessed by IHC on BM trephine

specimens, but not by flow cytometry, e.g. cyclin D1 in MCL, nucleophosmin in acute myeloid leukaemia.

– It is not recommended that IHC be routinely performed on all trephine biopsy specimens.

• In-situ hybridisation and other molecular investigations.

Page 37: Bone Marrow biopsy – processing Dr Epari Sridhar Associate Professor Pathology

8/F with pancytopenia

Page 38: Bone Marrow biopsy – processing Dr Epari Sridhar Associate Professor Pathology
Page 39: Bone Marrow biopsy – processing Dr Epari Sridhar Associate Professor Pathology

MPO

Glycophorin

Page 40: Bone Marrow biopsy – processing Dr Epari Sridhar Associate Professor Pathology

Contents of the report• The aggregate length of the biopsy core, the macroscopic

appearance and adequacy, integrity and quality of the specimen should be recorded.

• The percentage cellularity, pattern of cellularity and any necrotic, fibrotic or haemorrhagic areas should be noted.

• Bone architecture should be commented on if abnormal. • The cellular composition should be described in terms of

location, relative proportions, morphology and pattern of differentiation for erythroid, myeloid, megakaryocytic lineages, lymphoid cells, plasma cells and macrophages.

• Any abnormal cells if present should be described.• The reticulin grade and the results of IHC and histochemical

stains, whether positive or negative, should be reported, if performed.

Page 41: Bone Marrow biopsy – processing Dr Epari Sridhar Associate Professor Pathology

Thank you